123 related articles for article (PubMed ID: 1673269)
1. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer.
Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M
Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269
[TBL] [Abstract][Full Text] [Related]
2. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
3. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
4. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
[TBL] [Abstract][Full Text] [Related]
5. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
6. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
8. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
9. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
Pålsson B; Masson P; Andrén-Sandberg A
Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.
Takasaki H; Tempero MA; Uchida E; Büchler M; Ness MJ; Burnett DA; Metzgar RS; Colcher D; Schlom J; Pour PM
Int J Cancer; 1988 Nov; 42(5):681-6. PubMed ID: 3053465
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
[TBL] [Abstract][Full Text] [Related]
14. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
15. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
16. [Ca 19-9 in the diagnosis of pancreatic carcinoma].
Meggiato T; Basso D; Pasquali C; Angonese C; Bellinvia S; Del Favero G; Fabris C; Di Mario F; Plebani M; Pedrazzoli S
Minerva Med; 1989 May; 80(5):431-4. PubMed ID: 2747969
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
18. [Effect of biliary obstruction and cholangitis on serum SPan-1 level].
Matsumoto S; Muranaka T; Hanada K; Matsuura Y; Oshiumi Y
Kaku Igaku; 1990 Dec; 27(12):1443-6. PubMed ID: 2290216
[TBL] [Abstract][Full Text] [Related]
19. The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.
Toshkov I; Mogaki M; Kazakoff K; Pour PM
Int J Pancreatol; 1994 Apr; 15(2):97-103. PubMed ID: 8071575
[TBL] [Abstract][Full Text] [Related]
20. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
